Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas
SC Ng, S Plamondon, A Gupta, D Burling, MA Kamm
Alimentary Pharmacology and Therapeutics | WILEY | Published : 2009
Declaration of personal interests: Michael Kamm has served as a speaker, a consultant and an advisory board member for Abott Centocor, Scherring Plough and UCB. Permission to use Inflammatory Bowel Disease Questionnaire in this study was obtained from McMaster University. Declaration of funding interests: This study was funded in part by Scherring-Plough UK with an unrestricted educational grant. Schering-Plough UK had no knowledge of the nature, content or results of the study.